Biotech entity

DelveInsight Business Research

Company

pharma is the sole category represented across all 1 tracked stories. Aparna Thakur is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are better corroborated than the beat average, carrying 3 original sources each against 2.4 for the same window.

Last mentioned: Feb 19, 2026

Entity pulse

Recent coverage · DelveInsight Business Research

1 story
6 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about DelveInsight Business Research

pharma is the sole category represented across all 1 tracked stories. Aparna Thakur is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are better corroborated than the beat average, carrying 3 original sources each against 2.4 for the same window. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window. We currently track 1 Biotech story that mention DelveInsight Business Research, all published on February 19, 2026.

Stories tracked
1
Sources per story
3

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 27 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering DelveInsight Business Research. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning DelveInsight Business Research 1

Pharma Positive

PKU Market Set for Decade of Growth as Innovative Therapies Target Unmet Needs

The global Phenylketonuria (PKU) market is projected to expand significantly through 2034, fueled by a robust pipeline of next-generation therapies and enhanced diagnostic screening. With the United States leading in diagnosed prevalence, major players like BioMarin, PTC Therapeutics, and Jnana are racing to address the metabolic limitations of current standard-of-care treatments.

3 sources

Source: admin (in) · prnewswire.com

DelveInsight Business Research is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.